Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Lonez

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|June 15, 2017
Exploiting natural killer group 2D receptors for CAR T-cell therapyBenjamin Demoulin, W James Cook, Joana Murad, et al.
Haematologica|April 29, 2018
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patientDavid A Sallman, Jason Brayer, Elizabeth M Sagatys, et al.
Leukemia|September 15, 2025
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasiaDaniel Pollyea, Tessa Kerre, Dries Deeren, et al.
Cellular and Molecular Life Sciences : CMLS|May 8, 2019
Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4Malvina Pizzuto, Caroline Lonez, Alberto Baroja-Mazo, et al.
Cellular and Molecular Life Sciences : CMLS|July 25, 2019
Correction to: Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4Malvina Pizzuto, Caroline Lonez, Alberto Baroja-Mazo, et al.
European Journal of Immunology|April 5, 2008
DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4Tetsuya Tanaka, Amandine Legat, Emmanuelle Adam, et al.
Neoplasia (New York, N.Y.)|September 9, 2010
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expressionBenjamin Le Calvé, Michal Rynkowski, Marie Le Mercier, et al.
Current Research in Translational Medicine|April 8, 2018
Celyad's novel CAR T-cell therapy for solid malignanciesCaroline Lonez, Alain Hendlisz, Leila Shaza, et al.
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 1, 2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing StrategiesLorraine Springuel, Caroline Lonez, Bertrand Alexandre, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|June 15, 2017
Exploiting natural killer group 2D receptors for CAR T-cell therapyBenjamin Demoulin, W James Cook, Joana Murad, et al.
Haematologica|April 29, 2018
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patientDavid A Sallman, Jason Brayer, Elizabeth M Sagatys, et al.
Leukemia|September 15, 2025
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasiaDaniel Pollyea, Tessa Kerre, Dries Deeren, et al.
Cellular and Molecular Life Sciences : CMLS|May 8, 2019
Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4Malvina Pizzuto, Caroline Lonez, Alberto Baroja-Mazo, et al.
Cellular and Molecular Life Sciences : CMLS|July 25, 2019
Correction to: Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4Malvina Pizzuto, Caroline Lonez, Alberto Baroja-Mazo, et al.
European Journal of Immunology|April 5, 2008
DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4Tetsuya Tanaka, Amandine Legat, Emmanuelle Adam, et al.
Neoplasia (New York, N.Y.)|September 9, 2010
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expressionBenjamin Le Calvé, Michal Rynkowski, Marie Le Mercier, et al.
Current Research in Translational Medicine|April 8, 2018
Celyad's novel CAR T-cell therapy for solid malignanciesCaroline Lonez, Alain Hendlisz, Leila Shaza, et al.
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 1, 2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing StrategiesLorraine Springuel, Caroline Lonez, Bertrand Alexandre, et al.
Pageof 5